Molecular markers are an increasingly important part of gynecological cancer diagnosis. In this test-specific episode of the "Answers From the Lab" podcast, Sounak Gupta, M.B.B.S., Ph.D., explains why Mayo Clinic Laboratories' gynecological NGS panels are a cost-effective way to inform prognosis and individualized treatment.

"These panels fill a hole in our test menu with regards to certain disease states where we may want to test for just a handful of genes," Dr. Sounak says. "Our large cancer panel, which is over 500 genes, would give us this information. But we wanted to make a very focused, cost-effective test for patients with gynecologic malignancies."

Mayo Clinic Laboratories consulted gynecologic surgeons, medical oncologists, and pathologists to determine which genes to include in the ovarian and gynecological panels.

"Whether it's ovarian cancer or endometrial cancer, we've paid particular attention to biomarkers that can lead to improved patient management," Dr. Sounak says. "The focus ultimately is to have the best test for each patient."

Listen to learn more about Mayo Clinic Laboratories' gynecological NGS panels.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MCGYN | MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 49 genes.

MCECP | MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 19 genes.

MCOCP | MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

• Provides therapeutic insights based on assessment of 14 genes.

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less